Baxalta Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Baxalta Inc (Baxalta) is a biopharmaceutical company that develops, manufactures and commercializes therapies for orphan diseases. The company offers products for the treatment of orphan diseases related to cancer, and hematological and immunological diseases. It offers treatment for hemophilia, bleeding disorders, alpha-1 antitrypsin deficiency, immune deficiencies, burns and shock, other chronic and acute medical conditions, and treatment for acute lymphoblastic leukemia. Baxaltas pipeline includes biologics with innovative mechanisms, and advanced technology platforms such as gene therapy and biosimilars. The company sells its products in North America, South America, Europe and Asia-Pacific. The company conducts research through Baxalta Global Innovation and R&D Center in Cambridge, Massachusetts. Baxalta is headquartered in Bannockburn, Illinois, the US.

Baxalta Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

2
List of Tables 4
List of Figures 5
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Baxalta Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Baxalta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Baxalta Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Baxalta Acquires Oncaspar Portfolio from Sigma-Tau Finanziaria for USD900 Million 12
Venture Financing 13
OncoResponse Raises Additional USD3 Million in Series A Financing 13
Suppremol Raises US$20.6 Million In Series D Financing 14
AesRx Raises US$1.35 Million In Venture Financing 15
Chatham Therapeutics Secures US$0.2 Million In Venture Financing 16
AesRx Secures An Additional US$0.12 Million In Venture Financing 17
Partnerships 17
TR-Pharm Enters into Distribution Agreement with Sigma-Tau Rare Disease 17
Baxalta Enters into Agreement with Precision Biosciences 18
Baxalta Enters into Agreement with Symphogen 19
Novimmune Enters into Research Agreement with Baxalta 19
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 20
Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment 21
Licensing Agreements 22
SuppreMol Exercises Option For Licensing Agreement With Bayerische For RA Antibody 22
Equity Offering 23
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 23
Baxalta Invests in OncoResponse 24
Debt Offering 25
Baxalta Raises USD375 Million in Private Placement of 2% Notes Due 2018 25
Baxalta Raises USD1 Billion in Private Placement of 2.875% Notes Due 2020 26
Baxalta Raises USD500 Million in Private Placement of 3.6% Notes Due 2022 27
Baxalta Raises USD1.75 Billion in Private Placement of 4% Notes Due 2025 28
Baxalta Raises USD1 Billion in Private Placement of 5.25% Notes Due 2045 29
Baxalta Raises USD375 Million in Private Placement of Floating Rate Notes Due 2018 30
Asset Transactions 31
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 31
Acquisition 32
Shire Acquires Baxalta for USD32 Billion 32
Baxter International Acquires SuppreMol for USD225 Million 34
Baxter Acquires AesRx 35
Baxter International To Acquire Chatham Therapeutics From Asklepios BioPharma For US$70 Million 36
Baxalta Inc - Key Competitors 38
Key Employees 39
Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 43
Financial Announcements 43
Apr 28, 2016: Baxalta Exceeds Guidance and Delivers Strong Sales and Earnings for First Quarter 2016 43
Feb 16, 2016: Baxalta Posts Strong Fourth Quarter 2015 Sales and Earnings; Positive Momentum Continues with Achievement of Key Milestones 45
Government and Public Interest 47
Jun 27, 2016: BIRD - Israel-U.S. Binational Industrial R&D Foundation to Invest $7.5 Million in 9 New Projects 47
Other Significant Developments 48
Apr 21, 2016: Baxalta Supports Research to Raise Awareness of Treatment Burden on Patients during the Sixth Annual World Primary Immunodeficiency Week 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List Of Tables


Baxalta Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Baxalta Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Baxalta Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Baxalta Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Baxalta Acquires Oncaspar Portfolio from Sigma-Tau Finanziaria for USD900 Million 12
OncoResponse Raises Additional USD3 Million in Series A Financing 13
Suppremol Raises US$20.6 Million In Series D Financing 14
AesRx Raises US$1.35 Million In Venture Financing 15
Chatham Therapeutics Secures US$0.2 Million In Venture Financing 16
AesRx Secures An Additional US$0.12 Million In Venture Financing 17
TR-Pharm Enters into Distribution Agreement with Sigma-Tau Rare Disease 17
Baxalta Enters into Agreement with Precision Biosciences 18
Baxalta Enters into Agreement with Symphogen 19
Novimmune Enters into Research Agreement with Baxalta 19
Teijin Enters into Co-Development Agreement with Sigma-Tau Pharma for EZN-2279 20
Baxter Enters Into Co-Development Agreement With Chatham Therapeutics For Factor IX Hemophilia B Gene Therapy Treatment 21
SuppreMol Exercises Option For Licensing Agreement With Bayerische For RA Antibody 22
Opsona Therapeutics Raises USD10.58 Million in Private Placement of Shares 23
Baxalta Invests in OncoResponse 24
Baxalta Raises USD375 Million in Private Placement of 2% Notes Due 2018 25
Baxalta Raises USD1 Billion in Private Placement of 2.875% Notes Due 2020 26
Baxalta Raises USD500 Million in Private Placement of 3.6% Notes Due 2022 27
Baxalta Raises USD1.75 Billion in Private Placement of 4% Notes Due 2025 28
Baxalta Raises USD1 Billion in Private Placement of 5.25% Notes Due 2045 29
Baxalta Raises USD375 Million in Private Placement of Floating Rate Notes Due 2018 30
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 31
Shire Acquires Baxalta for USD32 Billion 32
Baxter International Acquires SuppreMol for USD225 Million 34
Baxter Acquires AesRx 35
Baxter International To Acquire Chatham Therapeutics From Asklepios BioPharma For US$70 Million 36
Baxalta Inc, Key Competitors 38
Baxalta Inc, Key Employees 39
Baxalta Inc, Subsidiaries 41

List Of Figures


Baxalta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Baxalta Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Baxalta Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Baxalta Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Baxalta Inc (Baxalta) is a biopharmaceutical company that develops, manufactures and commercializes therapies for orphan diseases. The company offers products for the treatment of orphan diseases related to cancer, and

USD 250 View Report

Tesla, Inc - Enterprise Tech Ecosystem Series

Tesla, Inc - Enterprise Tech Ecosystem SeriesTesla is leveraging digital technologies to innovate automotive industry by popularizing electric vehicles and by enhancing the usage of renewable energy storage solutions. The

USD 1495 View Report

PDL BioPharma Inc - Strategic SWOT Analysis Review

PDL BioPharma Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available